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Abstract We report a temporary decrease in twitch
response following reversal of rocuronium-induced neu-
romuscular block with a small dose of sugammadex in our
dose-finding study in pediatric patients. A 19-month-old
female infant (9.6 kg, 80 cm) was scheduled for elective
cheiloplasty surgery. Anesthesia was induced with nitrous
oxide 50 % and sevoflurane 5 % and maintained with air,
oxygen, sevoflurane 3 %, and fentanyl (total, 3 lg/kg).
Neuromuscular monitoring was performed at the adductor
pollicis muscle after induction of anesthesia but before the
administration of rocuronium. Total dose of rocuronium
during the surgery was 0.9 mg/kg. Neuromuscular block
was reversed with 0.5 mg/kg sugammadex when one
response was observed with post-tetanic count stimulation.
Twitch responses after sugammadex administration
showed a temporary decrease after its initial recovery.
Maximum decreases in twitch responses were observed
17 min after initial dose of sugammadex. Twitch responses
recovered to their control values after additional doses of
3.5 mg/kg sugammadex (4 mg/kg in total). Time from
sugammadex administration to maximum decreases in
twitch responses is earlier than has been reported in adults
(20–70 min). It is demonstrated that following neuromus-
cular block reversal with insufficient dose of sugammadex,
there is a possibility of the recurrence of residual paralysis
within less than 20 min in pediatric patients.
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Introduction
Sugammadex, a modified c-cyclodextrin, specifically
antagonizes the neuromuscular block of steroidal neuro-
muscular blocking agents such as rocuronium and vecu-
ronium [1]. Its efficacy in infants and children is reported
to be similar to adults in a Phase III A study [2]. Moreover,
sugammadex can reverse even a profound rocuronium-
induced neuromuscular block [3]. However, the optimal
dose of sugammadex to reverse profound neuromuscular
block in pediatric patients has not been determined. There
are risks of recurarization and recurrence of neuromuscular
block when an insufficient dose of sugammadex was
administered. It has been reported that recurrence of neu-
romuscular block was observed by using a small dose of
sugammadex in adult patients [4, 5]. We describe a case of
temporary decreases in twitch height and train-of-four
(TOF) ratio after reversal of rocuronium-induced neuro-
muscular block with a small dose of sugammadex in our
sugammadex dose-finding study in pediatric patients.
Case reports
After informed consent, the patient’s parents agreed to
participate in our dose-finding clinical study of sugamma-
dex in pediatric patients approved by our medical ethics
committee.
A 19-month-old female infant (9.6 kg, 80 cm, ASA
Class 1) was scheduled for elective cheiloplasty surgery.
She had no neuromuscular disorders and had not received
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any drug known to affect neuromuscular junction. The
patient received no premedication.
Anesthesia was induced with nitrous oxide 50 % and
sevoflurane 5 %, and maintained with air, oxygen, sevo-
flurane 3 %, and fentanyl (total 3 lg/kg). An intravenous
cannula was inserted on the dorsum of the hand after the
induction. Neuromuscular monitoring at the adductor pol-
licis muscle was performed by using TOF-Watch SX
(Organon, Dublin, Ireland) acceleromyography after
induction of anesthesia but before the administration of
rocuronium. The transducer was attached to the thumb with
tape on the opposite side of the intravenous cannula. After
calibration and stabilization of the twitch responses,
0.6 mg/kg rocuronium was administered. The trachea was
intubated after the disappearance of twitch responses of the
TOF stimulation. An additional dose of 0.3 mg/kg rocu-
ronium was administrated once to maintain neuromuscular
block at less than two twitches of TOF. Peripheral skin
temperature was kept above 34 C by using a warming
mattress. End-tidal sevoflurane and CO2 were kept constant
until full recovery of neuromuscular block after surgery.
When the delicate part of the surgery was finished, the
neuromuscular monitor showed one twitch response in
post-tetanic count stimulation (1 PTC), and the neuro-
muscular block was reversed with 0.5 mg/kg sugammadex.
Total dose of rocuronium given during the surgery was
0.9 mg/kg. The recovery of the twitch height of the first
twitch (T1 height) and the TOF ratio to 50 and 39 %,
respectively, were within 6 min after sugammadex
administration. However, temporary decreases in T1 height
and TOF ratio were observed (Fig. 1). Maximum decrease
was observed 17 min after the first sugammadex adminis-
tration, and the values of T1 height and TOF ratio were
47 % and 29 %, respectively. T1 height and TOF ratio were
the same values at 6 and 26 min after the first sugammadex
administration. At the end of the surgery (57 min after the
first sugammadex administration), an additional 2 mg/kg
sugammadex was administered to complete the reversal of
the neuromuscular block. TOF ratio recovered to 90 % at
46 s after the second sugammadex administration. How-
ever, at the same moment, T1 height did not recover to its
control value. T1 height and TOF ratio recovered to their
control values after another dose of 1.5 mg/kg sugamma-
dex (4 mg/kg in total). The trachea was extubated
uneventfully after full recovery of the neuromuscular
block.
Discussion
The patient in this report was enrolled in our sugammadex
dose-finding study for pediatric patients. The patient was in
the group to which 0.5 mg/kg sugammadex was given to
the patients at 1–2 PTC. Our protocol for tracheal extu-
bation was to administer at least total 4 mg/kg of sug-
ammadex (recommended dose to reverse neuromuscular
block when 1–2 PTC) before that point. It is demonstrated
that a temporary decrease in twitch response was observed
during the time course in the reversal of rocuronium-
induced neuromuscular block with a small dose of sug-
ammadex in pediatric patients. The same event has been
reported in adults [4, 5]. In these articles, the maximum
decreases in T1 height and TOF ratio were observed
approximately 20–70 min after sugammadex administra-
tion. In our patient, time from the small dose of sug-
ammadex administration to maximum decreases in T1
height and TOF ratio was 17 min, respectively. We dem-
onstrate that a temporary decrease in twitch response also
occurs in pediatric patients after a small dose of sug-
ammadex administration. These phenomena may be
explained by redistribution of rocuronium from peripheral
to central and effect-site compartments. Also, the time
from sugammadex administration to maximum decrease of
twitch response in pediatric patients was earlier than has
been reported in adults. These time differences may be
produced by the differences of pharmacokinetic and phar-
macodynamic profiles of neuromuscular blocking agents
between adults and pediatric patients [6]. It is clinically
Fig. 1 Progress of T1 height and train-of-four (TOF) ratio during
surgery. A temporary decrease in twitch response after administration
of a small dose of sugammadex (0.5 mg/kg) was observed. Initial
dose of sugammadex was administered when one twitch response was
observed with post-tetanic count. Additional doses of sugammadex
(2 and 1.5 mg/kg) were administered before extubation. Solid blue
lines represent the first twitch of the train-of-four (TOF); red dots
represent TOF ratio. Roc rocuronium, Sug sugammadex
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important to know that the time from sugammadex
administration to maximum decrease in twitch response
differs between pediatric patients and adults when the dose
of sugammadex given is insufficient.
Not the T1 height but the TOF ratio recovered to its
control value after the second dose of sugammadex
(3.5 mg/kg in total). A total dose of 4 mg/kg of sug-
ammadex was required for the recovery of T1 height and
TOF ratio to their control values. It has been reported that
full recovery of the TOF ratio is observed when T1 height
is still depressed after the reversal of neuromuscular block
by sugammadex [7, 8]. Therefore, it is important to confirm
full and constant recovery of twitch height as well as
recovery of TOF ratio C0.9. It is also demonstrated that at
least 4 mg/kg sugammadex was required to reverse neu-
romuscular block when 1–2 PTC in this pediatric patient.
We conclude that a temporary decrease in twitch
response may occur during reversal of rocuronium-induced
neuromuscular block with a small dose of sugammadex in
pediatric patients. Also, the time from small-dose sug-
ammadex administration to maximum decrease of twitch
response in pediatric patients was less than 20 min.
Therefore, following neuromuscular block reversal with
sugammadex, residual paralysis may occur earlier in
pediatric patients than in adult patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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